NEUROCRINE BIOSCIENCES INC

NBIX - CIK 0000914475

Market cap$16.17 B

Rank#700

SEC filings2,097

NEUROCRINE BIOSCIENCES INC trades as NBIX and has a market capitalization of $16.17 B, making it the #700 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.86B, up 21.4% from the prior year and net income of $478.60M. This page tracks NEUROCRINE BIOSCIENCES INC through 2,097 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$2.86BFY 2025

Net income (latest FY)$478.60MFY 2025

Operating cash flow (latest FY)$782.70MFY 2025

Total assets (latest FY)$4.63BFY 2025

Net margin16.7%latest FY

Financial performance

Over the last 9 fiscal years NEUROCRINE BIOSCIENCES INC's revenue grew from $15.00M to $2.86B, a compound annual growth rate of 79.2%. Net profit margin expanded from -940.6% to 16.7% over the same period - every figure below comes from the company's audited annual filings.

NBIX annual revenueView details

Key statistics

Market cap: $16.17 B
Share price (derived)market cap / shares outstanding: $160.86
P/E ratio (trailing FY): 33.8
EPS (diluted)FY 2025: $4.67
Shares outstandingas of 2026-04-28: 0.10B
Total equityas of 2026-03-31: $3.41B
Return on equity: 14.0%
Cash & equivalentsas of 2026-03-31: $266.50M

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-26
Insider trade	4	2026-05-21
Insider trade	4	2026-05-21
Insider trade	4	2026-05-21
Insider trade	4	2026-05-21
Insider trade	4	2026-05-21
Insider trade	4	2026-05-21
Insider trade	4	2026-05-21

Browse the full filing history (2,097 filings)

Recent press releases

2025 Annual Report2026-05-18
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | Neurocrine Biosciences
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics2026-05-18
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | Neurocrine Biosciences
2025 Annual Report2026-05-06
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | Neurocrine Biosciences
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results2026-05-05
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results | Neurocrine Biosciences
2025 Annual Report2026-05-05
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 | Neurocrine Biosciences

Similar companies

The largest companies sharing NEUROCRINE BIOSCIENCES INC's SEC industry classification (biological products, (no diagnostic substances)).

AMGNAmgen Inc.$183.41 B NBIX vs AMGN

GILDGilead Sciences, Inc.$151.05 B NBIX vs GILD

ARGXargenx SE$53.35 B NBIX vs ARGX

RVMDRevolution Medicines, Inc.$30.65 B NBIX vs RVMD

BIIBBiogen Inc.$28.68 B NBIX vs BIIB

Frequently asked questions

What is NEUROCRINE BIOSCIENCES INC's market cap?

NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of $16.17 B as of 2026-06-10, ranking #700 among US-listed companies.

How much revenue does NEUROCRINE BIOSCIENCES INC make?

NEUROCRINE BIOSCIENCES INC reported revenue of $2.86B for fiscal year 2025, an increase of 21.4% year over year.

Is NEUROCRINE BIOSCIENCES INC profitable?

Yes. NEUROCRINE BIOSCIENCES INC reported net income of $478.60M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.